Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Prospective multicenter study of camrelizumab in gastrointestinal malignancies
ChiCTR2000032189Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of camrelizumab in gastrointestinal cancer, hepatocellular carcinoma (HCC), gastric cancer (GC) and 1 more, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: progression-free survival and objective response rate. Started Dec 2019; status: recruiting.
02
Drugs
camrelizumab
03
Conditions
gastrointestinal cancerhepatocellular carcinoma (HCC)gastric cancer (GC)esophageal cancer
Beyond the preview
Go deeper on ChiCTR2000032189.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032189.